Nachrichten zur Biogen Inc. Aktie

Heres Why Biogen Inc. (BIIB) is a Strong Value Stock

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Heres why…

How Investors May Respond To Stoke Therapeutics (STOK) NEJM Data And 2027 FDA Filing Timeline

In recent days, Stoke Therapeutics and Biogen reported that data on the investigational Dravet syndrome medicine zorevunersen were published in…

Biogen Aktie: (K)ein Muss im Depot?

Bad Marienberg (www.aktiencheck.de) - Biogen: Kurszielerhöhung - Was weiß BMO Capital, was der Markt übersieht?Die Aktie von Biogen Inc. (ISIN:…

Biogen forecasts annual profit above estimates as Leqembi sales pick up

Biogen forecast 2026 profit above Wall Street estimates on Friday, banking on demand for newer medicines and its Alzheimers treatment…

Sales of Leqembi® totaled 20.7 billion yen in the fourth quarter 2025

Stockholm, Sweden, February 6, 2026 – BioArctic ABs (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today published the preliminary global…

Stocks making the biggest moves midday: Biogen, Rivian, Bank of America, Airbnb & more

These are the stocks posting the largest moves in midday trading.…

Biogen Aktienanalyse: Startet jetzt die Biotech-Rally 2026? Kursziel 225 USD!

Bad Marienberg (www.aktiencheck.de) - Biogen-Aktienanalyse: Goldman Sachs erhöht Kursziel auf 225 USD – Rückenwind für 2026!Die Goldman Sachs hat am…

Biogen: Competing With Eli Lillys Kisunla, Safety Gives Market Edge

…

Biogen Aktie: Morgan Stanley hebt Kursziel auf 156 USD - Kommt 2026 die Trendwende?

New York (www.aktiencheck.de) - Biogen-Aktienanalyse von Morgan Stanley:Der Analyst Terence Flynn von Morgan Stanley hat das Kursziel für die Biogen-Aktie…

Biogen Aktie: Analystenwarnung! HSBC sieht Risiko für Gewinne

London (www.aktiencheck.de) - Biogen-Aktienanalyse von HSBC:Die Analysten von HSBC stufen die Aktie von Biogen Inc. (ISIN: US09062X1037, WKN: 789617, Ticker-Symbol:…

New Data Presented at the Clinical Trials on Alzheimer’s Disease (CTAD) Conference 2025 Confirms Pharmacological Effect of LEQEMBI® (lecanemab-irmb) on Neurotoxic A? Protofibrils in CSF

TOKYO and CAMBRIDGE, Mass., Dec. 02, 2025 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito,…

Biogen Inc. (BIIB) Presents at Evercore 8th Annual Healthcare Conference Transcript

…

Institut: Alzheimer-Medikament Lecanemab von Biogen hat keinen Zusatznutzen

BERLIN/KÖLN (dpa-AFX) - Schlechte Nachrichten für den US-Hersteller Biogen und seinen japanischen Partner Eisai: Ein…

Nvidia, Microsoft, Apple, Zillow, Biogen: What brokers said this week

…

Biogen shares could climb on Leqembi uptake

Biogen Inc (NASDAQ:BIIB, XETRA:IDP) could see its stock move higher over the next two years as progress on its Alzheimer’s…

Biogen to gain from Novo Nordisk Alzheimer’s failure, says Jefferies By Investing.com

Biogen to gain from Novo Nordisk Alzheimer’s failure, says Jefferies…

Biogen Aktie: Piper Sandler erhöht Kursziel kräftig - doch warum bleibt das Rating "neutral"?

Bad Marienberg (www.aktiencheck.de) - Biogen: Was Anleger jetzt wissen müssenBiogen Inc. (ISIN: US09062X1037, WKN: 789617, Ticker-Symbol: IDP, NASDAQ-Symbol: BIIB) gehört…

“LEQEMBI®” (lecanemab) IV Maintenance Dosing for the Treatment of Early Alzheimer’s Disease Approved in the United Kingdom

TOKYO and CAMBRIDGE, Mass., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito,…

Stifel upgrades biotech stock on a narrative shift in Alzheimer’s treatment

Stifel sees Biogen stock rallying nearly 32% from here.…

Biogen Q3 2025 Quartalszahlen: 67% Umsatzplus bei neuen Therapien - Alzheimer-Mittel LEQEMBI mit Rekordwachstum

Bad Marienberg (www.aktiencheck.de)???? Biogen im Aufschwung: Neues Momentum und klare Vision - warum Analyst Phil Nadeau weiterhin auf "BUY" setztBiogen…

Biogen trims annual profit forecast on expected hit from R&D-related charges

Biogen cut its annual profit forecast on Thursday, as it expects to take a hit of $1.25 per share from…

Sales of Leqembi® totaled 18 billion yen in the third quarter 2025

Stockholm, Sweden, October 30, 2025 – BioArctic ABs (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today published the preliminary global…

Samsung Bioepis wird BYOOVIZ® (Ranibizumab) ab Januar 2026 in Europa vermarkten

INCHEON, Korea--(BUSINESS WIRE)--Samsung Bioepis Co., Ltd. gab heute bekannt, dass das Unternehmen mit Biogen einen Kaufvertrag (Asset Purchase Agreement, APA)…

J.L. Bainbridge Exits Most of Biogen Stake as Biotech Stock Eyes Turnaround

Key PointsFlorida-based J. L. Bainbridge sold 119,376 shares of Biogen for an estimated $16.1 million in the third quarter.After the…

Biogen Aktie: Biotech-Sektor im Aufwind - Kursziel steigt

New York (www.aktiencheck.de) - Biogen-Aktienanalyse von der Citigroup:Die Analysten der Citigroup stufen die Aktie von Biogen Inc. (ISIN: US09062X1037, WKN:…

Can Biogen Stock Rebound as New Drugs Aim to Offset MS Sales Declines?

Biogens new drugs Leqembi, Skyclarys and Zurzuvae are driving fresh momentum, but MS and Spinraza declines cloud its growth path.…

Biogen - BIIB: Leqembi erhält Zulassungen in China & Australien!

Pullback-Setup mit Bullenflagge! Neuausrichtung bei Biogen (BIIB): Alcyone Therapeutics für rund 85 Millionen USD übernommen & Rückzug aus AAV-basierten Gentherapieprojekten!…

Biogen Aktie: BofA-Analyst erhöht Kursziel - Wo Chancen locken und wo die Vorsicht herkommt

Bad Marienberg (www.aktiencheck.de) - Biogen: Eine Absage an WunschdenkenBiogen Inc. (ISIN: US09062X1037, WKN: 789617, Ticker-Symbol: IDP, NASDAQ-Symbol: BIIB) steht nach…

Erste Patienten bekommen Alzheimer-Mittel Lecanemab

BERLIN (dpa-AFX) - Seit gut einem Monat ist das Alzheimer-Medikament Lecanemab der Hersteller Biogen und Eisai in Deutschland…

“LEQEMBI®” (lecanemab) IV Maintenance Dosing for the Treatment of Early Alzheimer’s Disease Approved in China

TOKYO and CAMBRIDGE, Mass., Sept. 28, 2025 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito,…

Jefferies initiates Biogen stock with Buy rating, $190 price target By Investing.com

Jefferies initiates Biogen stock with Buy rating, $190 price target…

Biogen Inc. (BIIB) Presents at Bernstein 2nd Annual Global Healthcare Conference Transcript

…

Biogen Aktie: FDA-Bremse nur kurzer Stopp - Kommt die Spinraza-Zulassung doch bald?

eNew York (www.aktiencheck.de) - Biogen-Aktienanalyse der Citigroup:Citigroup habe das Schreiben der US-Arzneimittelbehörde FDA an Biogen Inc. (ISIN: US09062X1037, WKN: 789617,…

BIIBs sNDA for Higher Dose of SMA Drug Spinraza Gets FDAs CRL

FDA issues CRL to Biogens regulatory filing seeking approval for a higher dose of SMA drug, Spinraza. The company plans…

Biogen-Medikament gegen Wochenbettdepression in der EU zugelassen

BRÜSSEL (dpa-AFX) - Frauen mit Wochenbettdepression haben in der EU künftig Zugang zu einem neuen Medikament.…

Marktstart für Alzheimer-Mittel Lecanemab in Deutschland

BERLIN (dpa-AFX) - Der zur Alzheimer-Therapie zugelassene Antikörper Lecanemab kommt am 1. September in Deutschland offiziell…

Biogen: Strong Q2 Doesnt Change The Math On Eroding MS Portfolio

…

Ionis (IONS) Q2 Revenue Soars 101%

Key PointsIonis Pharmaceuticals (NASDAQ:IONS) reported Q2 2025 GAAP revenue and non-GAAP earnings per share that exceeded analyst expectations by wide…

Sales of Leqembi® totaled 23.1 billion yen in the second quarter 2025

Stockholm, Sweden, July 31, 2025 – BioArctic ABs (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today published the preliminary global…

Analysts Estimate Biogen Inc. (BIIB) to Report a Decline in Earnings: What to Look Out for

Biogen (BIIB) doesnt possess the right combination of the two key ingredients for a likely earnings beat in its upcoming…

Biogen investing $2B to expand operations in RTP

Biogen employs more than 1,500 workers and another 400 contractors at its Triangle campuses.…

Biogen to Highlight Scientific Progress Across Alzheimer’s Disease at the Alzheimer’s Association International Conference 2025

CAMBRIDGE, Mass., July 21, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced upcoming scientific presentations at…

Biogen to invest $2 billion in RTP, open new factory in 2025

Biogen Inc. has announced a $2 billion investment to expand its manufacturing capabilities at Research Triangle Park (RTP), marking its…

Biogen beefs up North Carolina manufacturing ahead of potential drug tariff storm

Biogen will invest $2 billion more in its existing manufacturing plants in North Carolina, the drugmaker said on Monday, as…

Drugmaker Biogen to invest $2 billion more in North Carolina

Biogen will invest an additional $2 billion in its existing manufacturing in North Carolina, the drugmaker said on Monday, as…

Biogen to invest $2 billion more in North Carolina

Drugmaker Biogen said on Monday it will invest an additional $2 billion in its existing manufacturing footprint in North Carolinas…

Biogen Announces $2 Billion Manufacturing Investment in North Carolina’s Research Triangle Park in Conjunction with its 30th Anniversary

CAMBRIDGE, Mass., July 21, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) – today announced it intends to invest…

dpa-AFX ProFeed